Search

everythinglearnresearchcommunity

for

Search:↓

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

The user experienced hair loss possibly due to scalp damage and tried natural treatments with limited success. They reported noticeable hair thickening after using a laser treatment device, suggesting it may be effective, especially for those on finasteride.

Finasteride is effective for DHT/AR-driven hair loss but not for chromosome 20-driven cases, where treatments like minoxidil, prostaglandin analogs, and low-level laser therapy may be more beneficial. Genetic testing can help determine the underlying cause of hair loss to tailor treatment effectively.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

Low-level laser therapy (LLLT) is debated for hair regrowth, with some users suggesting it should be combined with treatments like minoxidil and finasteride for effectiveness. Many users express skepticism about LLLT's efficacy and cost, emphasizing the need for the correct wavelength and quality devices.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

Dutasteride significantly reduces DHT levels in hair follicles, potentially more effectively than previously thought. The discussion highlights differences in DHT measurements and the impact on hair loss treatment.

Pyrilutamide from Ligand Chem was used by several individuals to address hair loss, with mixed results and no significant side effects reported. Some users switched to Minoxidil Max for better value, while others noted no hair growth or only a reduction in shedding.

The user is seeking advice on a hair loss treatment called Ell Cranell, which contains Alfatradiol. Another user shared information from a study stating that Alfatradiol only slows down or stabilizes hair loss, but does not increase hair density or thickness.

LLLT (low-level laser therapy) is as effective or better than traditional minoxidil treatment for hair growth, with fewer side effects and improved long-term compliance due to milder adverse effects. Studies show LLLT increases hair density more than minoxidil, but drawbacks include the initial cost and the need for long-term use to see results.

Dutasteride users have mixed results in hair loss treatment, with some experiencing improvements and others worsening. Some report metabolic changes like weight gain or diabetes, while others have no significant side effects.

Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

The user switched from finasteride to 2.5 mg dutasteride daily and added 1% pyrilutamide to address persistent scalp itch, but the itch remains. They also use 2% ketoconazole and 2.5% selenium sulfide shampoo for temporary relief.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

The conversation discusses hair regrowth using 2-deoxy-d-ribose (2DDR) combined with minoxidil, with some users noting new hair growth. The original poster has been using minoxidil for 12 years and is considering combining 2DDR with finasteride, despite past side effects.

The user switched from finasteride to dutasteride for hair loss and saw significant improvement in under two months. They also microneedle, take supplements including collagen and vitamin D3, use ketoconazole shampoo, and noticed accidental hair regrowth with retinol application on their face.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

Clascoterone is suggested as an alternative for those who experience side effects from finasteride and dutasteride. It is not widely available yet, but some users are obtaining it from compounding pharmacies or suppliers like Echemi.

Some hair loss may be linked to chromosome 20, which isn't affected by DHT blockers like finasteride. Treatments like minoxidil, microneedling, and genetic testing are suggested, but their effectiveness for this type of hair loss is uncertain.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

The user has been using Dutasteride for over a year for hair loss and is considering a hair transplant if it doesn't work. Suggestions include adding Minoxidil and microneedling, but some advise against a transplant as the current treatment seems effective.

Genetic variations influence how people respond to dutasteride for hair loss, with some benefiting more from finasteride. Dutasteride is effective for most, but genetic differences may cause it to be less effective for some.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.